BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9762343)

  • 1. Multifactorial mechanisms of drug resistance in tumor cell populations selected for resistance to specific chemotherapeutic agents.
    Cory AH; He AW; Cory JG
    Adv Enzyme Regul; 1998; 38():3-18. PubMed ID: 9762343
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanisms of drug resistance to inhibitors directed at the individual subunits of ribonucleotide reductase.
    Carter GL; Thompson DP; Cory JG
    Cancer Commun; 1989; 1(1):13-20. PubMed ID: 2701080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ribonucleotide reductase inhibitors on the growth of human colon carcinoma HT-29 cells in culture.
    Matsumoto M; Tihan T; Cory JG
    Cancer Chemother Pharmacol; 1990; 26(5):323-9. PubMed ID: 2208572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of biochemical modulation of drug combinations directed at the ribonucleotide reductase site on leukemia L1210 cell growth in culture.
    Sato A; Carter GL; Bacon PE; Cory JG
    Adv Enzyme Regul; 1983; 21():259-70. PubMed ID: 6400064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific inhibition of the subunits of ribonucleotide reductase as a new approach to combination chemotherapy.
    Cory JG; Sato A; Lasater L
    Adv Enzyme Regul; 1980; 19():139-50. PubMed ID: 7039256
    [No Abstract]   [Full Text] [Related]  

  • 6. The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model.
    Cory JG; Sato A; Carter GL; Bacon PE; Montgomery JA; Brown NC
    Adv Enzyme Regul; 1985; 23():181-92. PubMed ID: 3907303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
    Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
    Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
    Cory AH; Sato A; Thompson DP; Cory JG
    Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the differential mechanisms of inhibition of ribonucleotide reductase by specific inhibitors of the non-heme iron subunit.
    Sato A; Bacon PE; Cory JG
    Adv Enzyme Regul; 1984; 22():231-41. PubMed ID: 6089512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
    Carter GL; Cory JG
    Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity.
    Finch RA; Liu MC; Cory AH; Cory JG; Sartorelli AC
    Adv Enzyme Regul; 1999; 39():3-12. PubMed ID: 10470363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY).
    Moore EC; Hurlbert RB
    Pharmacol Ther; 1985; 27(2):167-96. PubMed ID: 3898152
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of combinations of drugs that inhibit Ehrlich tumor cell ribonucleotide reductase.
    Sato A; Cory JG
    Cancer Res; 1981 May; 41(5):1637-41. PubMed ID: 6783298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on growth of L1210 cells in culture.
    Sato A; Carter GL; Bacon PE; Cory JG
    Cancer Res; 1982 Nov; 42(11):4353-7. PubMed ID: 6751522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mammalian ribonucleotide reductase by cis-diamminedichloroplatinum(II).
    Chiu CS; Chan AK; Wright JA
    Biochem Cell Biol; 1992 Dec; 70(12):1332-8. PubMed ID: 1299271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting the mRNA levels for the non-heme iron and effector-binding subunits of ribonucleotide reductase.
    Carter GL; Cory JG
    Adv Enzyme Regul; 1992; 32():227-40. PubMed ID: 1496919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime.
    Tihan T; Elford HL; Cory JG
    Adv Enzyme Regul; 1991; 31():71-83. PubMed ID: 1877400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts.
    Wakisaka N; Yoshizaki T; Raab-Traub N; Pagano JS
    Int J Cancer; 2005 Sep; 116(4):640-5. PubMed ID: 15818619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of the repair of potentially lethal damage in plateau-phase Chinese hamster cells by 2-chlorodeoxyadenosine.
    Tanabe K; Hiraoka W; Kuwabara M; Matsuda A; Ueda T; Sato F
    J Radiat Res; 1988 Sep; 29(3):172-81. PubMed ID: 2905006
    [No Abstract]   [Full Text] [Related]  

  • 20. Revisiting ribonucleotide reductase as a target to enhance radiation and chemotherapy anti-tumor activity.
    Sznol M
    Cancer J; 2003; 9(4):247-50. PubMed ID: 12967134
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.